Fibrodysplasia Ossificans Progressiva With Acvr1 Mutation Therapeutics
1. Sohonos patent expiration
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva; Reduction of heterotopic ossification in patients with fibrodysplasia ossificans (myositis) pro...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622959 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| US10864194 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| US10292954 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US9789074 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US9314439 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US12023312 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US12201614 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| US12458626 | IPSEN | NA |
Jun, 2037
(11 years from now) | |
| US12138245 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Dosage: CAPSULE
More Information on Dosage
SOHONOS family patents
